Tue . 19 Jun 2019

Peginterferon alfa-2a

peg interferon alfa 2a, peg interferon alfa-2a roche
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92% For hepatitis B it may be used alone It is given by injection under the skin

Side effects are common They may include headache, feeling tired, depression, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever Severe side effects may include psychosis, autoimmune disorders, blood clots, or infections Use with ribavirin is not recommended during pregnancy Pegylated interferon alfa-2a is in the alpha interferon family of medications It is pegylated to protect the molecule from breakdown

Pegylated interferon alfa-2a was approved for medical use in the United States in 2002 It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system The wholesale cost in the developing world is between 50000 and 4,80000 USD for 12 weeks In the United States this costs about 9,25000 USD, while in the United Kingdom 12 weeks costs the NHS about 149280 pounds

Contents

  • 1 Medical uses
    • 11 Host genetic factors
    • 12 Other infections
  • 2 Manufacture
  • 3 Research
  • 4 References
  • 5 External links

Medical uses

This drug is approved around the world for the treatment of chronic hepatitis C including people with HIV co-infection, cirrhosis, 'normal' levels of ALT and has recently been approved in the EU, US, China and many other countries for the treatment of chronic hepatitis B It is also used in the treatment of certain T-cell lymphomas, particularly mycosis fungoides

Peginterferon alfa-2a is a long acting interferon Interferons are proteins released in the body in response to viral infections Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system

Host genetic factors

For genotype 1 hepatitis C treated with pegylated interferon-alfa-2a or pegylated interferon-alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment This finding, originally reported in Nature, showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others Another report in Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus

Other infections

Has also been used for Middle East respiratory syndrome and hepatitis E

Manufacture

It is pegylated with a branched 40 kg/mol PEG chain

Research

A Cochrane Review sought to determine whether interferon alfa-2a could be used as a treatment for individuals with neovascular age-related macular degeneration They found no evidence of improved visual acuity with potential harm

References

  1. ^ a b c d e f g h "Peginterferon Alfa-2a Professional Patient Advice - Drugscom" wwwdrugscom Archived from the original on 16 January 2017 Retrieved 12 January 2017 
  2. ^ "Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics SPC - eMC" wwwmedicinesorguk Archived from the original on 13 January 2017 Retrieved 12 January 2017 
  3. ^ a b British national formulary : BNF 69 69 ed British Medical Association 2015 p 639 ISBN 9780857111562 
  4. ^ a b c "Peginterferon alfa-2a Pegasys - Treatment - Hepatitis C Online" wwwhepatitiscuwedu Archived from the original on 23 December 2016 Retrieved 12 January 2017 
  5. ^ "WHO Model List of Essential Medicines 19th List" PDF World Health Organization April 2015 Archived PDF from the original on 13 December 2016 Retrieved 8 December 2016 
  6. ^ "Inclusion of the injectable formulation of peginterferon alfa-2a and -2b is proposed for the treatment of hepatitis C among adults" PDF whoint p 11 Archived PDF from the original on 13 January 2017 Retrieved 12 January 2017 
  7. ^ Ge D, Fellay J, Thompson AJ, et al 2009 "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance" Nature 461 7262: 399–401 doi:101038/nature08309 PMID 19684573 
  8. ^ Thomas DL, Thio CL, Martin MP, et al 2009 "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus" Nature 461 7265: 798–801 doi:101038/nature08463 PMC 3172006  PMID 19759533 
  9. ^ "Peginterferon Alfa Monograph for Professionals - Drugscom" wwwdrugscom Archived from the original on 16 January 2017 Retrieved 12 January 2017 
  10. ^ Reddy U, Krzystolik M 2006 "Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration" Cochrane Database Syst Rev 1: CD005138 doi:101002/14651858CD005138pub2 PMID 16437522 

External links

  • Interferon and hepatitis c at pegasyscom
  • PMPRB at pmprb-cepmbgcca
  • Chemical structure at hepalifecom
  • Pegasys at the US National Library of Medicine Medical Subject Headings MeSH
  • Pharmacy and pharmacology portal
  • Medicine portal

peg interferon alfa 2a, peg interferon alfa 2a side effects, peg interferon alfa 2a vs 2b, peg interferon alfa 2a vs beta 2b, peg interferon alfa-2a roche


Peginterferon alfa-2a Information about

Peginterferon alfa-2a


  • user icon

    Peginterferon alfa-2a beatiful post thanks!

    29.10.2014


Peginterferon alfa-2a
Peginterferon alfa-2a
Peginterferon alfa-2a viewing the topic.
Peginterferon alfa-2a what, Peginterferon alfa-2a who, Peginterferon alfa-2a explanation

There are excerpts from wikipedia on this article and video

Random Posts

The San Francisco Examiner

The San Francisco Examiner

The San Francisco Examiner is a longtime daily newspaper distributed in and around San Francisco, Ca...
Frederator Films

Frederator Films

Frederator Films is an animation studio founded by Fred Seibert as part of Frederator Studios, with ...
John Hasbrouck Van Vleck

John Hasbrouck Van Vleck

John Hasbrouck Van Vleck March 13, 1899 – October 27, 1980 was an American physicist and mathematici...
Christian Lacroix

Christian Lacroix

Christian Marie Marc Lacroix French pronunciation: ​kʁistjɑ̃ lakʁwa; born 16 May 1951 is a Fren...